Clear-Cell Renal-Cell Carcinoma (ccRCC) Clinical Trials

7 recruitingLast updated: June 18, 2026

There are 7 actively recruiting clear-cell renal-cell carcinoma (ccrcc) clinical trials across 14 countries. Studies span Phase 1, Phase 2. Top locations include Jacksonville, Florida, United States, Phoenix, Arizona, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Clear-Cell Renal-Cell Carcinoma (ccRCC) Trials at a Glance

7 actively recruiting trials for clear-cell renal-cell carcinoma (ccrcc) are listed on ClinicalTrialsFinder across 6 cities in 14 countries. The largest study group is Phase 1 with 4 trials, with the heaviest enrollment activity in Jacksonville, Phoenix, and Boston. Lead sponsors running clear-cell renal-cell carcinoma (ccrcc) studies include Regeneron Pharmaceuticals, Brian Rini, and Exelixis.

Browse clear-cell renal-cell carcinoma (ccrcc) trials by phase

Treatments under study

About Clear-Cell Renal-Cell Carcinoma (ccRCC) Clinical Trials

Looking for clinical trials for Clear-Cell Renal-Cell Carcinoma (ccRCC)? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Clear-Cell Renal-Cell Carcinoma (ccRCC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Clear-Cell Renal-Cell Carcinoma (ccRCC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+4 more
Kura Oncology, Inc.300 enrolled38 locationsNCT06026410
Recruiting
Phase 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Solid Tumor+7 more
Exelixis1,314 enrolled122 locationsNCT05176483
Recruiting
Phase 2

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Clear-Cell Renal-Cell Carcinoma (ccRCC)Metastatic Renal Cell Carcinoma (mRCC)Advanced Renal Cell Carcinoma (aRCC)
Brian Rini120 enrolled1 locationNCT07188896
Recruiting
Phase 1Phase 2

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

MelanomaAdvanced Solid TumorsClear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals240 enrolled11 locationsNCT06413680
Recruiting
Phase 2

Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC

Neoadjuvant TherapyClear-Cell Renal-Cell Carcinoma (ccRCC)Vorolanib
Sun Yat-sen University21 enrolled1 locationNCT07386158
Recruiting
Phase 1Phase 2

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Metastatic Castration-resistant Prostate Cancer (mCRPC)Clear-Cell Renal-Cell Carcinoma (ccRCC)
Regeneron Pharmaceuticals345 enrolled21 locationsNCT03972657
Recruiting

Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma

Renal Cell Carcinoma (RCC)Clear-Cell Renal-Cell Carcinoma (ccRCC)
The Affiliated Hospital of Qingdao University40 enrolled1 locationNCT06916624